RayzeBio, a Bristol Myers Squibb company, plans to invest more than $173 million in central Indiana operations and build a major new manufacturing facility. The company will establish an approximately 450,000-square-foot facility
More
Roivant Sciences (ROIV) and its partner Priovant Therapeutics have secured FDA approval for Lisraya, a first-in-class oral treatment for the rare autoimmune disease dermatomyositis. The U.S. Food and Drug Administration approved Lisraya,
More
O9 Solutions Inc. has secured an important early legal victory in its trade secret lawsuit against enterprise software giant SAP SE (SAP) in the Northern District of Texas. The case centres on
More
Wells Fargo’s Legal Specialty Group has released its six-month 2026 survey, and the headline numbers show Biglaw enjoying one of its strongest years on record. Revenue across the Am Law 200 climbed
More
A new lawsuit has been filed against law firm Troutman Pepper Locke, with an associate claiming the firm moved the goalposts on partnership after he survived a serious cardiac event at the
More
Colman’s Mustard is being put up for sale by its parent company Unilever as part of a sweeping merger between the FTSE 100 giant’s food division and US spice giant McCormick. Bankers
More
Abrdn Healthcare Opportunities Fund (THQ) Wins Rating Upgrade On High-Yield Healthcare Income Appeal
Abrdn Healthcare Opportunities Fund, trading on the New York Stock Exchange under the ticker THQ, has received a rating upgrade from analysts covering the closed-end fund space. The fund focuses on generating
More
Dividend investors are increasingly turning their attention to high-yield stocks that appear undervalued when measured against forward earnings expectations for 2027. In an environment where interest rates remain a key concern for
More
Uefa has dramatically escalated its campaign to remove Gianni Infantino by initiating the first formal legal steps toward a criminal complaint against the Fifa president. Lawyers acting for European football’s governing body
More
Gilead Sciences has secured regulatory approval from the US Food and Drug Administration for Bixlenvo, a new once-daily single-tablet HIV treatment combining two established compounds. The pill pairs bictegravir, the active backbone
More